What the SPRINT Trial Showed About a Blood Pressure Target of 120

The Systolic Blood Pressure Intervention Trial (SPRINT) randomly assigned 9,361 adults at increased cardiovascular risk, but without diabetes or prior stroke, to one of two systolic blood pressure targets: below 120 mm Hg (intensive) or below 140 mm Hg (standard). The intensive group had fewer major cardiovascular events and lower death from any cause, and the trial was stopped early because that benefit was clear. That benefit was accompanied by higher rates of specific harms, including low blood pressure, fainting, electrolyte disturbances, and kidney injury. How much SPRINT should change any one person's target depends on reading its numbers, its methods, and its trade-offs together rather than in isolation.

This article is educational and not medical advice.

What the trial tested and what it found

Participants had a systolic reading of 130 mm Hg or higher plus elevated cardiovascular risk from age, kidney disease, known vascular disease, or a high risk score. The primary outcome was a composite: myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. In the original 2015 report in the New England Journal of Medicine, the two groups separated as intended. At one year, mean systolic pressure was 121.4 mm Hg in the intensive group and 136.2 mm Hg in the standard group.

The primary event rate was 1.65 percent per year with intensive treatment versus 2.19 percent per year with standard treatment, a hazard ratio of 0.75 (95 percent confidence interval 0.64 to 0.89). Death from any cause was also lower, with a hazard ratio of 0.73 (95 percent confidence interval 0.60 to 0.90). A data monitoring board recommended stopping the intervention early, after a median of about 3.3 years, once the cardiovascular signal crossed a prespecified boundary.

The 2021 final report added events that were still being adjudicated when the first analysis was locked, plus a period of post-trial observation. The direction held. During the trial, the primary event rate was 1.77 versus 2.40 percent per year (hazard ratio 0.73), and all-cause mortality was 1.06 versus 1.41 percent per year (hazard ratio 0.75). One nuance emerged: when trial and post-trial follow-up were combined, the difference in heart failure between groups no longer reached significance, a reminder that a composite can be driven by some components more than others.

Why "stopped early" is a caveat, not a headline

Stopping a trial for benefit sounds like the strongest possible result, and here the effect was consistent and biologically plausible. But early stopping has a known statistical cost. Trials halted at a moment when the treatment effect happens to look large can overstate the true size of benefit, because the decision to stop is itself tied to a favorable interim reading. SPRINT's estimate should be read as reliable in direction and meaningful in magnitude, while allowing that the real-world benefit may sit toward the more modest end of the confidence interval. This is a general principle of evidence appraisal, not a criticism unique to this trial.

The measurement question that changed how people read SPRINT

The single most important methodological detail is how blood pressure was measured. SPRINT used automated office readings, with the participant resting and often unobserved, and the device taking several readings on its own. This method tends to produce values several mm Hg lower than the hurried, attended reading taken in a typical clinic visit, where conversation, a short or absent rest period, and the presence of staff all nudge the number upward.

The practical consequence is that a target below 120 in SPRINT does not translate cleanly to a target below 120 taken with a cuff during a routine appointment. A person managed to SPRINT-style automated readings near 120 might read somewhat higher if measured the ordinary way, and treating a conventional office reading down to 120 could mean pushing true pressure lower than the trial ever tested. Debate after publication centered on exactly how large this gap is, with estimates varying widely. The honest summary is that the target is inseparable from the method used to reach it, and applying the number without the method risks overtreating.

Weighing benefit against harm

SPRINT is a useful case study in holding two true things at once. The intensive strategy reduced serious cardiovascular events and death. It also caused more of certain adverse events: hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure were each more frequent in the intensive group. Notably, injurious falls were not more common, which matters because fear of falls is a frequent reason clinicians hesitate to lower pressure in older adults.

Two ideas help translate this. First, absolute versus relative benefit. A hazard ratio of roughly 0.75 is a substantial relative reduction, but the absolute yearly difference in the primary outcome was well under one percentage point, because the underlying event rate was already modest. The higher a person's baseline risk, the more that same relative reduction converts into meaningful absolute benefit, which is why SPRINT enrolled a higher-risk population and why its findings extend most confidently to similar people.

Second, harms scale with individual physiology. A younger person with resilient kidneys and stable standing blood pressure faces different odds than someone with chronic kidney disease or a tendency to feel faint on standing. SPRINT reported average effects across a trial population; it cannot tell any single reader where their personal balance point sits.

What SPRINT does and does not settle

SPRINT provides strong evidence that, for adults resembling its participants, a lower systolic target reduces cardiovascular events and mortality, at the cost of more of several specific adverse events. It does not establish that everyone benefits equally, that the same target suits people it did not study, such as those with diabetes, prior stroke, or advanced frailty, or that a clinic cuff reading of 120 carries the same meaning as a SPRINT automated reading of 120. Later guideline debates and subsequent studies have wrestled with exactly these boundaries. Read carefully, SPRINT is a strong result with clear edges, and respecting those edges is what separates using the evidence from overreaching it.